![PDF) Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial PDF) Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial](https://i1.rgstatic.net/publication/253332043_Traumeel_vs_diclofenac_for_reducing_pain_and_improving_ankle_mobility_after_acute_ankle_sprain_A_multicentre_randomised_blinded_controlled_and_non-inferiority_trial/links/547364990cf24bc8ea1b0cd9/largepreview.png)
PDF) Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial
![A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain - Hans-Georg Predel, Bruno Giannetti, Bernd Seigfried, A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain - Hans-Georg Predel, Bruno Giannetti, Bernd Seigfried,](https://journals.sagepub.com/cms/10.1177/0300060513487639/asset/images/large/10.1177_0300060513487639-fig1.jpeg)
A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain - Hans-Georg Predel, Bruno Giannetti, Bernd Seigfried,
![Randomized, double-blind, noninferiority study of diclofenac diethylamine 2.32% gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily in patients with acute ankle sprain | BMC Musculoskeletal Disorders | Full Text Randomized, double-blind, noninferiority study of diclofenac diethylamine 2.32% gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily in patients with acute ankle sprain | BMC Musculoskeletal Disorders | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12891-022-06077-z/MediaObjects/12891_2022_6077_Fig2_HTML.png)
Randomized, double-blind, noninferiority study of diclofenac diethylamine 2.32% gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily in patients with acute ankle sprain | BMC Musculoskeletal Disorders | Full Text
![Topical Anti-inflammatories Effective, & Safer, than Pain Pills | American Council on Science and Health Topical Anti-inflammatories Effective, & Safer, than Pain Pills | American Council on Science and Health](http://acsh.org/wp-content/uploads/2016/02/Ankle-Sprain-201x225.jpg)
Topical Anti-inflammatories Effective, & Safer, than Pain Pills | American Council on Science and Health
![Comparison of the Analgesic and Anti-Inflammatory Effects of Diclofenac Potassium versus Piroxicam versus Placebo in Ankle Sprain Patients | Semantic Scholar Comparison of the Analgesic and Anti-Inflammatory Effects of Diclofenac Potassium versus Piroxicam versus Placebo in Ankle Sprain Patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dcb8b0d7daaff5e8159d9bd7f98231e7ee9dfc29/3-Figure1-1.png)
Comparison of the Analgesic and Anti-Inflammatory Effects of Diclofenac Potassium versus Piroxicam versus Placebo in Ankle Sprain Patients | Semantic Scholar
![PDF) Diclofenac Epolamine plus Heparin Plaster versus Diclofenac Epolamine Plaster in Mild to Moderate Ankle Sprain A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicentre, Phase III Trial PDF) Diclofenac Epolamine plus Heparin Plaster versus Diclofenac Epolamine Plaster in Mild to Moderate Ankle Sprain A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicentre, Phase III Trial](https://i1.rgstatic.net/publication/47348743_Diclofenac_Epolamine_plus_Heparin_Plaster_versus_Diclofenac_Epolamine_Plaster_in_Mild_to_Moderate_Ankle_Sprain_A_Randomized_Double-Blind_Parallel-Group_Placebo-Controlled_Multicentre_Phase_III_Trial/links/53e29f860cf275a5fdda3a20/largepreview.png)